GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Interest Coverage

Sunho Biologics (HKSE:02898) Interest Coverage : 0 (At Loss) (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Sunho Biologics's Operating Income for the six months ended in Dec. 2024 was HK$-51.69 Mil. Sunho Biologics's Interest Expense for the six months ended in Dec. 2024 was HK$-0.38 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Sunho Biologics's Interest Coverage or its related term are showing as below:


HKSE:02898's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Sunho Biologics Interest Coverage Historical Data

The historical data trend for Sunho Biologics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sunho Biologics Interest Coverage Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23 Dec24
Interest Coverage
- - -

Sunho Biologics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24
Interest Coverage No Debt - - - -

Competitive Comparison of Sunho Biologics's Interest Coverage

For the Biotechnology subindustry, Sunho Biologics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunho Biologics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunho Biologics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Sunho Biologics's Interest Coverage falls into.


;
;

Sunho Biologics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sunho Biologics's Interest Coverage for the fiscal year that ended in Dec. 2024 is calculated as

Here, for the fiscal year that ended in Dec. 2024, Sunho Biologics's Interest Expense was HK$-0.98 Mil. Its Operating Income was HK$-108.21 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$4.97 Mil.

Sunho Biologics did not have earnings to cover the interest expense.

Sunho Biologics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Here, for the six months ended in Dec. 2024, Sunho Biologics's Interest Expense was HK$-0.38 Mil. Its Operating Income was HK$-51.69 Mil. And its Long-Term Debt & Capital Lease Obligation was HK$4.97 Mil.

Sunho Biologics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Sunho Biologics  (HKSE:02898) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Sunho Biologics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunho Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
Executives
Sunho Fortune Investments Limited 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Zhang Feng 2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited 2101 Beneficial owner

Sunho Biologics Headlines

No Headlines